Core Mechanism · Pharmacology

GLP-1 Receptor Agonists —
Mechanisms of Action

A comprehensive reference covering the biology of endogenous GLP-1, receptor pharmacology, intracellular signalling cascades, tissue-specific effects, and the structural basis of all licensed drug classes — including the dual GIP/GLP-1 agonism of tirzepatide.

Authors: S.K.H. Kazmi
Reviewed: February 2026
NICE NG28 · SfE 2024
34 min read
Section 01

Endogenous GLP-1

Biosynthesis, secretion, and physiological half-life

Glucagon-like peptide-1 (GLP-1) is an incretin hormone — a gut-derived peptide that augments glucose-stimulated insulin secretion. It was first isolated from intestinal extracts in the 1980s following the cloning of the proglucagon gene, and is now understood to be one of two principal incretins alongside glucose-dependent insulinotropic polypeptide (GIP).

💡
Clinical Pearl — The Incretin Effect
Oral glucose elicits 2–3× greater insulin secretion than an equivalent intravenous glucose infusion — a phenomenon called the incretin effect. This accounts for approximately 50–70% of postprandial insulin release in healthy individuals. In type 2 diabetes, the incretin effect is markedly diminished but not absent — a key pharmacological target.
Biosynthesis — Proglucagon Processing

GLP-1 is encoded within the proglucagon gene (GCG) on chromosome 2q36.3. The proglucagon precursor protein (180 amino acids) is cleaved post-translationally by prohormone convertase 1/3 (PC1/3) in intestinal L-cells, yielding:

Proglucagon Processing — Tissue-Specific Cleavage
PROGLUCAGON — 180 amino acids GRPP GLUCAGON IP-1 GLP-1 (7-36 amide) IP-2 GLP-2 Alpha cells → Glucagon L-cells → GLP-1 (active) PC2 PC1/3 Distal ileum · Colon · Proximal gut (minor)

Figure 1. Tissue-specific post-translational processing of proglucagon. PC1/3 in intestinal L-cells produces active GLP-1; PC2 in pancreatic alpha-cells yields glucagon.

Secretion — L-Cell Physiology

GLP-1 is secreted from enteroendocrine L-cells concentrated in the distal ileum and colon, with a smaller contribution from proximal gut L-cells. Plasma GLP-1 rises within 5–15 minutes of meal ingestion — a response that is too rapid for luminal nutrients to reach the distal gut, implicating vagal and neural cephalic phase signals in early secretion, with a sustained late peak driven by direct L-cell contact with lipids and carbohydrates.

⚠
DPP-4 Degradation — The Pharmacological Challenge
Native GLP-1 has a plasma half-life of <2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), which removes the N-terminal His-Ala dipeptide to yield the inactive metabolite GLP-1 (9-36 amide). This near-complete first-pass degradation was the principal barrier to therapeutic use — overcome in GLP-1 RAs by structural modification to resist DPP-4 cleavage.
Section 02

Receptor Structure & Distribution

Class B GPCR — tissue-specific expression pattern

The GLP-1 receptor (GLP-1R) is a class B (secretin family) G-protein coupled receptor encoded by the GLP1R gene on chromosome 6p21. It consists of 463 amino acids with a large extracellular N-terminal domain, seven transmembrane helices, and three intracellular loops — the structural basis for Gs-protein coupling and downstream cAMP signalling.

GLP-1 Receptor Tissue Distribution & Primary Effects
GLP-1R Class B GPCR Pancreas β-cells · α-cells Insulin ↑ · Glucagon ↓ CNS Hypothalamus · NTS Appetite ↓ · Satiety ↑ Heart Myocardium · Nodes HR ↑ mild · Cardioprotection Kidney Proximal tubule Natriuresis · GFR protection GI Tract Stomach · Intestine Gastric emptying ↓ Liver Hepatocytes HGP ↓ · Steatosis ↓

Figure 2. GLP-1 receptor tissue distribution. The GLP-1R is expressed in pancreatic β and α cells (primary metabolic target), CNS (satiety/appetite), myocardium, kidney proximal tubule, gastrointestinal tract, and liver. NTS = nucleus tractus solitarius; HGP = hepatic glucose production.

Section 03

Intracellular Signalling Cascade

cAMP–PKA axis, EPAC2, and ion channel modulation

GLP-1R activation initiates a canonical Gs-protein coupled signalling pathway, with secondary signalling through EPAC2 (exchange protein directly activated by cAMP). Together, these pathways converge on calcium-dependent insulin exocytosis and transcriptional regulation of beta-cell gene expression.

1
GLP-1 Binding to Extracellular Domain
GLP-1 (or a GLP-1 RA) binds the large N-terminal extracellular domain of GLP-1R. The peptide adopts an α-helical conformation, with the C-terminus engaging the extracellular domain and the N-terminus inserting into the transmembrane bundle to stabilise the active receptor conformation. Binding affinity (EC₅₀) for native GLP-1 is approximately 1–5 nmol/L.
Receptor activation
2
Gs-Protein Coupling → Adenylyl Cyclase Activation
Receptor conformational change activates the coupled heterotrimeric Gs-protein. The Gαs subunit dissociates and directly stimulates adenylyl cyclase (AC), catalysing the conversion of ATP to cyclic AMP (cAMP). Beta-cell cAMP rises 3–10-fold above basal within seconds of GLP-1 exposure.
Gs coupling
3
cAMP → PKA Activation
Elevated cAMP activates protein kinase A (PKA) by binding its regulatory subunits (RI/RII), releasing the active catalytic subunits. PKA phosphorylates multiple downstream targets including: KATP channel subunits (Kir6.2/SUR1) → channel closure; voltage-dependent Ca²⁺ channels → enhanced Ca²⁺ influx; and exocytotic machinery proteins (snapin, synapsin I) → lowered secretory threshold.
PKA axis
4
EPAC2 Pathway — PKA-Independent cAMP Signalling
cAMP also directly activates EPAC2 (Rap GEF), a guanine nucleotide exchange factor that activates Rap1 GTPase. EPAC2 signalling potentiates insulin secretion through: (i) sensitisation of the ryanodine receptor → enhanced Ca²⁺ release from endoplasmic reticulum; (ii) activation of phospholipase C-ε → IP₃/diacylglycerol production. EPAC2 is critical for the first-phase insulin secretion restoration seen with GLP-1 RAs.
EPAC2 axis
5
KATP Channel Closure → Membrane Depolarisation
PKA-phosphorylated KATP channels close, reducing K⁺ efflux and causing beta-cell membrane depolarisation. This activates voltage-gated Ca²⁺ channels (L-type VDCC), triggering Ca²⁺ influx. This mechanism is additive to — not independent of — glucose-stimulated KATP closure, explaining the glucose-dependency of the insulinotropic effect.
Ion channel modulation
6
Ca²⁺ Influx → Insulin Vesicle Exocytosis
Cytosolic Ca²⁺ elevation (from both VDCC influx and ER release) triggers SNARE-complex assembly (SNAP-25, syntaxin-1, VAMP-2) and fusion of insulin-containing secretory granules with the plasma membrane. GLP-1 signalling lowers the Ca²⁺ threshold for exocytosis and recruits reserve pool granules — thereby restoring both first-phase (rapid, 0–10 min) and second-phase (sustained, 10–120 min) insulin secretion, which are characteristically blunted in type 2 diabetes.
Insulin exocytosis
7
Nuclear Signalling — Beta-Cell Gene Transcription
PKA-activated CREB (cAMP response element-binding protein) translocates to the nucleus and upregulates transcription of PDX-1, NeuroD1, and Nkx6.1 — master regulators of beta-cell identity. This promotes insulin gene expression, beta-cell differentiation, and in preclinical models, beta-cell mass expansion through increased proliferation and reduced apoptosis (via PI3K/Akt pathway). Clinical translation of beta-cell preservation in humans remains under investigation.
Transcriptional regulation
⚗
Mechanism Note — Receptor Trafficking
Sustained GLP-1R agonism causes receptor internalisation via β-arrestin recruitment, reducing surface receptor density (homologous desensitisation). Biased agonism — favouring Gs over β-arrestin coupling — is an active area of drug development, aiming to preserve signalling potency during continuous exposure. Current licensed agents differ in their β-arrestin recruitment profiles, which may partly explain differences in durability of glycaemic effect.
Section 04

Pancreatic Effects

Beta-cell, alpha-cell, and delta-cell physiology

The pancreas is the primary pharmacological target of GLP-1 RAs. Effects span insulin secretion augmentation, glucagon suppression, and potential modification of islet cell mass — each with distinct mechanistic bases and clinical relevance.

Beta-Cell Effects — Insulin Secretion

GLP-1 RAs restore the biphasic insulin secretion pattern characteristically lost in T2DM. First-phase secretion (the acute spike within 10 minutes of glucose exposure) depends on readily-releasable granule pools; GLP-1 signalling through EPAC2 recruits these granules and lowers the Ca²⁺ trigger threshold. Second-phase secretion draws on reserve pool granules mobilised through both PKA and PI3K pathways.

HbA1c reduction (mono)
−1.0–1.8%
SUSTAIN programme · semaglutide
Fasting glucose reduction
−1.6mmol/L
vs placebo · SUSTAIN-1
Postprandial glucose (AUC)
−35%
Combined gastric + insulin effect
First-phase insulin response
+2.4×
vs baseline in T2DM subjects
Alpha-Cell Effects — Glucagon Suppression

GLP-1Rs are expressed on pancreatic alpha-cells, and their activation suppresses glucagon secretion in a glucose-dependent manner. Postprandial hyperglucagonaemia — a major contributor to fasting hyperglycaemia in T2DM via unopposed hepatic glucose production — is significantly attenuated. Crucially, counter-regulatory glucagon responses to hypoglycaemia are preserved because GLP-1-mediated glucagon suppression is glucose-dependent and attenuates at low plasma glucose.

📊
Evidence — Glucagon Suppression
Postprandial glucagon is reduced by approximately 30–50% with once-weekly semaglutide vs placebo (SUSTAIN-1). Fasting glucagon is reduced by 12–20%. Counter-regulatory responses to insulin-induced hypoglycaemia (plasma glucose <3.9 mmol/L) are maintained, consistent with the glucose-dependent mechanism of GLP-1R-mediated alpha-cell suppression.
Delta-Cell & Paracrine Effects

GLP-1R expression has also been identified on pancreatic delta-cells (which secrete somatostatin) and on the vagal afferents innervating the islets. The contribution of local paracrine somatostatin release to GLP-1-mediated glucagon suppression remains mechanistically debated, with evidence supporting both direct alpha-cell GLP-1R signalling and indirect somatostatin-mediated suppression as concurrent pathways.

Section 05

Extrapancreatic Effects

CNS, cardiovascular, renal, hepatic, and gastrointestinal

Tissue Receptor Expression Primary Effect Clinical Relevance
Hypothalamus Arcuate nucleus, PVN, lateral hypothalamic area Appetite suppression ↓ Food intake Weight loss 5–20%
Brainstem (NTS) Nucleus tractus solitarius Satiety signalling; nausea at supraphysiological doses Dose-dependent GI side effects
Stomach Myenteric plexus; smooth muscle Gastric emptying delay ↓ Motility Flattened PPG; anaesthetic risk
Myocardium GLP-1R on cardiomyocytes, endothelium Mild chronotropy ↑ HR +2–4 bpm; anti-inflammatory; ischaemic preconditioning SELECT: −20% MACE
Vasculature Endothelial cells; VSMCs Endothelial NO↑; anti-atherogenic; mild BP reduction ↓ 2–4 mmHg SBP CV risk reduction
Kidney (PCT) Proximal convoluted tubule Natriuresis ↓ Na reabsorption; reduced SGLT2 expression; anti-inflammatory FLOW: −24% eGFR decline
Liver Hepatocytes (low-level expression) Hepatic glucose production ↓; reduced hepatic lipogenesis; MASLD improvement Steatohepatitis benefit
Adipose tissue Adipocytes (indirect via CNS) Lipolysis modulation; visceral fat preferential reduction ↓ Fat mass Metabolic risk reduction
💡
Clinical Pearl — CNS Mechanism of Weight Loss
Hypothalamic GLP-1R activation in the arcuate nucleus inhibits orexigenic NPY/AgRP neurons and activates anorexigenic POMC/CART neurons, reducing appetite drive and caloric intake. Crucially, GLP-1 RAs appear to reduce food reward salience — blunting hedonic eating — via mesolimbic dopamine pathway modulation, explaining reductions in binge eating and food cravings observed clinically before significant weight loss occurs.
Section 06

Glucose-Dependent Insulinotropism

The mechanistic basis of hypoglycaemia safety

The defining safety advantage of GLP-1 RAs — near-absent hypoglycaemia risk in monotherapy — is a direct consequence of the glucose-dependent nature of GLP-1R-mediated insulin secretion. This is not a pharmacokinetic property but a fundamental signalling constraint.

GLP-1 RAs amplify glucose-stimulated insulin secretion — they do not drive insulin secretion in the absence of glucose. At plasma glucose below ~4–4.5 mmol/L, the insulinotropic effect is physiologically silent.

Mechanistic Basis — KATP Channel Requirement

The critical insight lies in the cooperative gating of KATP channels. For GLP-1-mediated PKA phosphorylation of KATP channels to translate into membrane depolarisation, the channels must already be partially closed by ATP generated from glucose oxidation. At low plasma glucose:

Glucose-Dependence — KATP Channel Logic
LOW GLUCOSE (< 4 mmol/L) KATP channels OPEN (low ATP) GLP-1R + PKA active No depolarisation → No Ca²⁺ influx Insulin secretion ABSENT ✓ No hypoglycaemia risk HIGH GLUCOSE (> 6 mmol/L) KATP channels PARTIAL CLOSURE GLP-1R + PKA amplifies closure Depolarisation → Ca²⁺ → Exocytosis Insulin secretion AMPLIFIED ✓ Glucose normalised

Figure 3. The glucose-dependent gating mechanism explaining why GLP-1 RAs do not cause hypoglycaemia in monotherapy. PKA-mediated KATP channel phosphorylation requires existing partial channel closure by glucose-derived ATP to produce membrane depolarisation.

⚠
Caution — Combination with Sulphonylureas or Insulin
When GLP-1 RAs are combined with sulphonylureas or insulin, hypoglycaemia risk is significantly increased — not from the GLP-1 RA itself, but from the sulphonylurea's glucose-independent KATP blockade or insulin's direct action. NICE NG28 recommends reducing sulphonylurea dose by 50% when initiating a GLP-1 RA. The GLP-1 RA retains its intrinsic glucose-dependence, but the co-agent does not.
Section 07

Drug-Specific Pharmacology

Structural basis of receptor activity and extended half-life

All licensed GLP-1 RAs share the core pharmacological mechanism of GLP-1R agonism but differ fundamentally in their structural basis for DPP-4 resistance, albumin-binding strategy, elimination half-life, and receptor activation kinetics. These differences translate into clinically relevant distinctions in dosing frequency, weight loss potency, and adverse effect profile.

Twice daily
Exenatide
Byetta · Bydureon (XR) · First in class
Origin
Exendin-4 (Gila monster)
GLP-1 Homology
53% sequence identity
Half-life (IR)
~2.4 hours
Half-life (XR)
~2 weeks (PLGA microspheres)
Structural Basis of Activity
Exenatide is a synthetic version of exendin-4, a peptide isolated from the venom of the Gila monster (Heloderma suspectum). It shares 53% sequence homology with human GLP-1 but critically differs at position 2: Gly replaces Ala, conferring resistance to DPP-4 cleavage. The extended-release formulation (Bydureon) encapsulates exenatide in poly(lactic-co-glycolic acid) microspheres for subcutaneous depot release, achieving once-weekly dosing through slow polymer degradation rather than pharmacokinetic modification of the peptide itself.
Once daily
Liraglutide
Victoza (T2DM) · Saxenda (obesity)
GLP-1 Homology
97% sequence identity
Modification
C16 fatty acid chain (Lys26)
Half-life
~13 hours
Albumin binding
>98% (non-covalent)
Structural Basis of Activity
Liraglutide is a 97% sequence-identical analogue of GLP-1(7-37), modified at two positions: Arg34Lys (prevents trypsin cleavage) and addition of a C16 palmitoyl fatty acid via a glutamate linker at Lys26. The fatty acid chain mediates non-covalent albumin binding, creating a large molecular complex (~70 kDa effective size) that resists renal filtration and dramatically extends half-life from <2 minutes to ~13 hours — sufficient for once-daily dosing. Self-aggregation into heptameric complexes at the injection site provides an additional depot effect, slowing subcutaneous absorption.
Once weekly · Oral available
Semaglutide
Ozempic (SC) · Wegovy (SC obesity) · Rybelsus (oral)
GLP-1 Homology
94% sequence identity
Modification
C18 fatty diacid · mini-PEG linker
Half-life
~7 days (165–184 h)
Albumin affinity
3–4× greater than liraglutide
Structural Basis of Activity
Semaglutide achieves the longest half-life of any approved GLP-1 RA through three structural innovations: (1) Aib8 substitution (α-aminoisobutyric acid at position 8) for superior DPP-4 resistance; (2) Arg34Lys mutation preventing proteolytic cleavage; (3) a C18 fatty diacid (via a short PEG spacer and glutamate linker at Lys26) providing markedly enhanced albumin binding compared with liraglutide's C16 chain. The result is >99% plasma protein binding, a ~7-day effective half-life, and once-weekly dosing. Oral semaglutide (Rybelsus) uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as an absorption enhancer that transiently raises gastric pH and increases mucosal membrane permeability, achieving ~1% bioavailability compared with subcutaneous injection — sufficient for clinically meaningful glycaemic and weight effects.
Once weekly
Dulaglutide
Trulicity · Fc-fusion technology
Structure
GLP-1 × 2 + IgG4 Fc fusion
Molecular weight
~60 kDa (large protein)
Half-life
~5 days (112 hours)
Special property
FcRn recycling → long t½
Structural Basis of Activity
Dulaglutide employs an entirely different strategy — rather than albumin binding, it uses IgG4 Fc fusion. Two modified GLP-1 molecules are linked to the Fc region of IgG4 via a small peptide connector. The large molecular size (~60 kDa) prevents renal filtration, while neonatal Fc receptor (FcRn) recycling — the same mechanism that extends IgG antibody half-lives — rescues dulaglutide from lysosomal degradation, yielding a ~5-day half-life and once-weekly dosing. The Fc region is further modified (Leu234Ala, Leu235Ala) to minimise Fc-effector functions and reduce immunogenicity.
Dual agonist · Once weekly
Tirzepatide
Mounjaro (T2DM) · Zepbound (obesity) · GIP/GLP-1 dual
Mechanism
GIP-R + GLP-1R dual agonism
GIP-R activity
Full agonist (EC₅₀ ~0.05 nM)
GLP-1R activity
Partial agonist (lower potency)
Max weight loss
Up to 22.5% (SURMOUNT-1)
Dual Agonism — A Distinct Mechanism Class
Tirzepatide represents a mechanistic advance beyond GLP-1 RA — it is a dual GIP/GLP-1 receptor co-agonist, acting as a full agonist at the GIPR and a partial agonist (with biased signalling characteristics) at GLP-1R. Its structure is based on the 39-amino-acid sequence of GIP with modifications for GLP-1R co-binding, extended by a C20 fatty diacid chain for albumin binding (~7-day half-life). The complementary mechanisms include: GIP-mediated potentiation of insulin secretion through its own cAMP pathway; GIP's adipocyte-level lipid metabolism modulation (reducing lipotoxicity); and GLP-1R-mediated appetite suppression and gastric emptying delay. The GIPR agonism also appears to paradoxically enhance GLP-1-mediated weight loss — likely through synergistic hypothalamic effects and adipose tissue energy handling — producing substantially greater weight reduction than selective GLP-1R agonism at equivalent tolerability.
Pharmacological Comparison
Property
Liraglutide
Semaglutide SC
Tirzepatide
Dosing
Once daily
Once weekly
Once weekly
t½
~13 h
~7 days
~5 days
HbA1c ↓
~1.1%
LEADER
~1.5–1.8%
SUSTAIN-1
~2.0–2.3%
SURPASS-2
Weight loss
~5–6%
Victoza dose
~10–15%
2.4 mg (Wegovy)
~15–22%
15 mg (SURMOUNT)
CV evidence
LEADER +
SELECT +
SURPASS-CVOT +
Oral form
No
Yes (Rybelsus)
In development
Section 08

Tirzepatide — Dual Agonism

GIP receptor pharmacology and synergistic weight loss

The GIP receptor (GIPR) is a class B GPCR structurally related to GLP-1R, and like GLP-1, GIP is an incretin hormone released from intestinal K-cells in the proximal duodenum. Despite comparable insulinotropic potency in healthy individuals, the incretin effect of GIP is paradoxically preserved in T2DM — unlike GLP-1 — but GIP-mediated insulin secretion may be blunted by GIP receptor downregulation in the setting of chronic hyperglycaemia.

⚗
The GIP Paradox — Why Dual Agonism Outperforms GLP-1 RA Alone
In isolation, GIPR agonism produces modest weight loss. Combined GIP+GLP-1R agonism produces supraphysiological weight loss that exceeds additive predictions — pointing to pharmacological synergy. Proposed mechanisms: (1) GIPR signalling in adipocytes promotes fat redistribution and fatty acid oxidation, reducing lipotoxicity that would otherwise limit GLP-1-mediated effects; (2) Combined hypothalamic activation through GIPR and GLP-1R in ARC/VMH produces greater appetite suppression than either pathway alone; (3) Tirzepatide's biased GLP-1R agonism (preferring Gs over β-arrestin) may reduce receptor desensitisation and maintain sustained signalling. Weight loss up to 22.5% was achieved in the SURMOUNT-1 trial at 15 mg, placing tirzepatide in the range of bariatric surgery for some endpoints.
📊
Evidence — SURMOUNT-1 (NEJM 2022)
2,539 adults with obesity (BMI ≥30) without T2DM randomised to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean weight loss: −15.0%, −19.5%, −20.9% vs −3.1% placebo. 37% of participants on 15 mg achieved ≥25% weight loss. These results substantially exceed published outcomes for any selective GLP-1 RA at licensed doses, supporting the additive/synergistic weight loss hypothesis of dual GIP/GLP-1 agonism.

References: Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism 2018. · Nauck MA et al. NEJM 2021. · Jastreboff AM et al. NEJM 2022 (SURMOUNT-1). · Lincoff AM et al. NEJM 2023 (SELECT). · Marso SP et al. NEJM 2016 (LEADER). · Holman RR et al. NEJM 2017 (SUSTAIN-6). · NICE NG28 February 2026. · SfE GLP-1 RA guidelines 2024. Data pertain to licensed adult doses in UK-approved indications unless stated.